Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) just unveiled an update.
Shanghai Haohai Biological Technology Co., Ltd. has announced its 2024 Annual General Meeting scheduled for June 10, 2025, where key resolutions will be considered, including the approval of the 2024 Annual Report, remuneration plans, and profit distribution. A significant proposal includes the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules, alongside granting the Board a mandate to repurchase H Shares, which could impact the company’s governance and shareholder value.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a company incorporated in the People’s Republic of China, operating in the biotechnology industry. It focuses on developing and providing biological products and technologies.
Average Trading Volume: 585,957
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.06B
See more insights into 6826 stock on TipRanks’ Stock Analysis page.